Clinical Research Directory

Inclusion Criteria: * Participant (or legally acceptable representative if applicable) provides written informed consent for the trial. * Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. * Archival tumor tissue sample or newly obtained \[core, incisional or excisional\] biopsy of a tumor lesion not previously irradiated has been provided. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Adequate organ function. Exclusion Criteria: * Pregnancy or breastfeeding * Aberration in a known targetable molecular driver. * Received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Received prior systemic anti-cancer therapy for metastatic disease. * Received prior radiotherapy within 2 weeks of start of study intervention. * Major surgery within 14 days. * Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy. * Known additional malignancy that is progressing or has required active treatment within the past 3 years. * Known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated or asymptomatic brain metastases may participate provided they are radiologically stable.